Gene Delivery Nanoparticles to Modulate Angiogenesis

Purpose: Angiogenesis is normally balanced by pro- and anti-angiogenic factors, but imbalance leads to aberrant angiogenesis in ischemia, tissue regeneration, cancer, and neovascular age-related macular degeneration (wet AMD). Gene therapy is a promising strategy to introduce exogenous nucleic acids that express or silence target agents, thereby engineering neovascularization in both directions. Non-viral gene delivery nanoparticles have been widely investigated, but clinical translation remains hampered by safety, delivery efficiency, and therapeutic effect. This review consolidates key targets, non-viral nanoparticle approaches, and preclinical/clinical applications for angiogenesis modulation. ---

Hypothesis: The central thesis is: if non-viral gene delivery nanoparticles are rationally engineered—using degradable polymers, targeting ligands, and optimized physicochemical properties—then they can safely and effectively deliver pro-angiogenic or anti-angiogenic nucleic acids to modulate angiogenesis in ischemic disease, tissue regeneration, cancer, and wet AMD. ---

Aims: - Summarize key pro-angiogenic and anti-angiogenic factors targeted for therapeutic angiogenesis and anti-angiogenesis gene therapy. - Review non-viral nanoparticle-mediated approaches to gene delivery. - Present recent gene therapy applications in preclinical and clinical trials for ischemia, tissue regeneration, cancer, and wet AMD. - Propose enhanced nanoparticle design strategies to improve efficacy and clinical translation. ---

Delivery system: Non-viral nanoparticle platforms: - Cationic polymers: Poly(ethylene imine) (PEI; linear and branched), poly(L-lysine) (PLL), poly(amidoamine) (PAMAM) dendrimers, poly(β-amino ester)s (PBAEs), chitosan, β-cyclodextrin, poly(vinyl pyrrolidone) (PVP), poly(arginine), elastin-like polypeptides, water-soluble lipopolymer (WSLP). - Biodegradable polymers: PLGA, polycaprolactone (PCL), Pluronic L64, dextran, hyaluronic acid hydrogels, collagen scaffolds. - Lipid-based systems: Cationic liposomes (DOTAP, cholesterol), PEGylated liposomes, lipid nanoparticles, microbubbles for ultrasound-targeted destruction. - Inorganic/hybrid: Quantum dots, mesoporous organosilica, nanohydroxyapatite, gold nanoparticles. - Cell-based delivery: Ex vivo transfected MSCs, EPCs, HUVECs, skeletal myoblasts, adipose-derived stromal cells (ASCs). Payloads: - Pro-angiogenic: VEGF, HIF-1α, HGF, FGF-1/2, PlGF, Ang1, PDGF-BB, SHh, adrenomedullin, eNOS, IL-10. - Anti-angiogenic: sFlt-1 (sVEGFR1), PEDF, endostatin, angiostatin, TIMP-2, vasostatin, Flt23k. - RNAi: siRNA/shRNA/miRNA against VEGF, VEGFR1, VEGFR2, HIF-1α, NF-κB p65, miR-132, etc. Targeting ligands: RGD/cRGD, anisamide, transferrin, Tat, activatable cell-penetrating peptides (ACPPs), MMP-sensitive peptides. Administration routes: Intramuscular, intramyocardial, intravenous, intravitreal, subretinal, intradermal/topical, ultrasound-targeted microbubble destruction. ---

Approach: Narrative review of preclinical and clinical literature. No primary experimental groups. Model systems discussed include: - In vitro: HUVECs, HRECs, RPE cells, MSCs, EPCs, myoblasts, ASCs, cancer cell lines. - In vivo: Mouse, rat, rabbit, pig, and monkey models of ischemic limb, myocardial infarction, wound healing, bone regeneration, cancer, and choroidal neovascularization (CNV)/wet AMD. - Clinical trials: Gene therapy trials for peripheral arterial disease, critical limb ischemia, myocardial ischemia, cancer, and wet AMD; mostly naked plasmid or viral vectors, with a growing number of non-viral approaches. ---

Key methods: Techniques highlighted across cited studies: - Transfection efficiency and gene expression (reporter genes, RT-PCR, fluorescence microscopy). - Capillary density, blood perfusion, vessel density, and collateral growth. - Infarct size and cardiac function (ejection fraction, left ventricular end-diastolic pressure). - Wound closure area, collagen deposition, cellularity, bone formation. - Tumor volume, microvessel density, VEGF mRNA/protein knockdown, survival. - CNV lesion area, leakage, lesion thickness, visual acuity. - Biodistribution, serum stability, cytotoxicity, and immune response. ---

Key results: - Ischemic limb: PEI/heparin-pVEGF nanoparticles increased capillary density >3-fold in mouse ischemic limb. PBAE-pVEGF-transfected HUVECs achieved 50% limb salvage vs 30% for lipo-pVEGF and 12.5% for PEI-pVEGF. - Myocardial infarction: WSLP-delivered hypoxia-inducible VEGF reduced infarct size by 36% in a rabbit myocardial infarct model compared with ligation-only control. - Wound healing: PBAE-SHH plasmid nanoparticles resulted in 100% wound closure at day 10, significantly greater than 85% for PBS/nonfunctional plasmid controls. PBAE-pVEGF-transfected ASCs accelerated wound closure and increased collagen deposition. - Cancer: PEI-PEG-RGD/pCMV-sFlt-1 nanoparticles achieved 7% injected dose in tumor, >3-fold tumor growth inhibition, and increased survival in colon carcinoma. PAMAM dendrimer carrying pAngiostatin/pTIMP-2 inhibited tumor growth by 96% vs empty plasmid. G-CD-PEG-AA-siVEGF produced 3-fold tumor suppression and >3.5-fold VEGF mRNA reduction vs non-targeted. UTMD-mediated shVEGFR2 reduced tumor volume by 40%. - Wet AMD/CNV: RGD-PLGA-pFlt23k nanoparticles regressed CNV area by 53% in primates and 43% in a murine sFlt-1-knockdown model, more than intravitreal anti-VEGF. PLGA-shHIF-1α reduced leakage by 50% and lesion thickness by 40% at day 14. - Clinical trials: VEGF gene therapy showed mixed results; some improvements in hemodynamics, skin ulcers, and claudication, but no consistent amputation reduction. HGF plasmid trial showed significant benefit in transcutaneous oxygen tension at 6 months but no differences in secondary endpoints. PEDF phase I trial in AMD showed minor inflammation, treatable ocular pressure increases, and inhibition of lesion growth over 12 months. ---

Interpretation: The authors conclude that non-viral gene delivery nanoparticles hold significant potential to modulate angiogenesis by shifting the balance of angiogenic signaling. They offer advantages over viral vectors and free nucleic acids, including improved stability, targeting, cellular internalization, customizability, and lower toxicity. However, clinical benefits have so far been modest. Challenges in dosing, transfection efficiency, safety, and incomplete understanding of angiogenesis biology in specific microenvironments limit translation. Further development of non-viral nanoparticles and deeper understanding of angiogenesis biology are needed to optimize genetic cargo selection and delivery. ---

Limitations: - Review, not primary study: No original experimental data; synthesizes published literature. - Clinical translation gap: Non-viral gene delivery for angiogenesis remains nascent; short list of clinical trials. - Efficacy barriers: Dosing, transfection efficiency, and therapeutic effect are still limiting factors. - Safety concerns: Uncontrolled long-term angiogenesis can cause edema, limb loss, and hemangiomas, especially with high VEGF expression. - Delivery barriers: Systemic delivery faces serum protein interactions, clearance, and off-target effects. - Tissue-specific barriers: Optimal nanoparticle properties for in vitro transfection may be poor for in vivo delivery (e.g., large, highly positive particles). - Complex biology: Incomplete understanding of angiogenesis in different microenvironments; need to target both endothelial and mural cells. - Limited clinical progress: Most clinical trials used naked plasmid or viral vectors; non-viral nanoparticle clinical translation is still limited.